Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp (NASDAQ: DRIO) is a leader in digital therapeutics, revolutionizing chronic condition management through data-driven health solutions. This news hub provides investors and healthcare professionals with essential updates on corporate milestones, clinical validations, and strategic partnerships.
Access timely press releases covering earnings reports, product innovations, and business expansions. Our curated collection includes updates on Dario's integrated platform developments, partnership announcements with healthcare providers, and regulatory milestones in digital health.
Key focus areas include advancements in personalized coaching technologies, behavioral health integrations, and outcomes from clinical studies. Stay informed about DarioHealth's progress in merging life sciences with digital tools to improve chronic care management for employers, payers, and patients.
Bookmark this page for direct access to verified corporate communications. Check regularly for updates on DRIO's market-moving developments in the rapidly evolving digital therapeutics sector.
DarioHealth (NASDAQ: DRIO) has successfully closed a $25.6 million private placement of convertible preferred stock, with significant participation from existing shareholders and accredited healthcare investors. The financing extends Dario's proforma cash balance to $40.6 million as of Q3 2024 and supports the company's strategy to achieve operational cash flow positive run rate by the end of 2025.
The placement involved issuing 18,805 shares of Preferred Stock at $1,000 per share with a $0.73 conversion price, and 6,800 shares at $1,000 per share with a $0.83 conversion price. Holders will receive a 10% quarterly dividend in common stock for the first four quarters, up to 40% total. The Preferred Stock will automatically convert to common stock after 12 months, subject to stockholder approval.
The company aims to focus on high-margin, scalable recurring revenues across B2B and pharma channels, supported by cost optimization efforts following the Twill merger.
DarioHealth Corp. (NASDAQ: DRIO) is expanding its presence in the weight-loss market by enhancing its GLP-1 offering with prescribing capabilities. The weight-loss market is projected to exceed $100 billion annually by 2030. Following the announcement, Dario's shares increased by nearly 14%.
The company's integrated solution combines behavior change programs with physician oversight for GLP-1 medications, addressing the growing demand from employers and consumers. According to a Mercer survey, 44% of large employers now cover obesity medications. Dario's approach aims to prevent weight regain after medication use by focusing on sustainable lifestyle changes.
The expansion targets both the employer market and direct-to-consumer segments, offering digital platform access and virtual care. The company also sees potential revenue opportunities through partnerships with pharmaceutical companies for data-driven insights and patient engagement.
DarioHealth (Nasdaq: DRIO) has announced a strategic collaboration with MediOrbis to enhance its GLP-1 behavior change solution by adding prescribing capabilities. This partnership creates a comprehensive medical weight loss program targeting employers and direct-to-consumer markets.
The collaboration comes as employer coverage of GLP-1 medications for weight loss expands, with 44% of large employers now covering obesity drugs according to a Mercer survey. The enhanced solution aims to ensure appropriate prescription of medications while providing behavior change support for sustainable weight loss outcomes.
The partnership positions Dario to drive recurring revenue through multiple channels, including employer-sponsored programs and direct-to-consumer offerings. The integrated solution combines virtual physician management with Dario's behavior change expertise to optimize outcomes and ROI for employers, while providing seamless access to care for individuals most likely to benefit from GLP-1 medications.
DarioHealth (Nasdaq: DRIO) has secured four new self-insured employer contracts, expected to go live in Q1 2025. These contracts cover Dario's complete platform suite, with clients opting for multi-condition offerings rather than single-condition solutions. The company projects to achieve approximately 25 new client signings in 2024, representing a 35% growth in client base compared to 2023.
These new contracts will contribute to recurring revenue starting in Q1 2025, furthering Dario's momentum in the Business-to-Business-to-Consumer (B2B2C) channel. According to Chief Commercial Officer Steven Nelson, these employer contracts support near-term growth, enhance gross margin growth, and expand user population reach.
DarioHealth (DRIO) reported strong Q3 2024 financial results with revenue of $7.42 million, up 18.7% from Q2 2024 and 111% year-over-year. The company reduced its GAAP operating loss by 25.7% to $12 million and non-GAAP operating loss by 33.3% to $7.1 million compared to Q2 2024. Key achievements include securing 10 new B2B2C clients and transforming the pharma channel into a recurring revenue model. The company expects a 38% reduction in operating expenses by Q1 2025 and remains on track to achieve operational cash flow breakeven by end of 2025. Gross margins for B2B2C business reached 83%, with full business gross margins at 52%.
DarioHealth Corp. (DRIO) announced a new collaboration with a top-six U.S. pharmaceutical company to utilize Dario Connect for enhancing patient engagement with a new psoriasis drug. The partnership marks a shift from milestone-based to recurring subscription revenue model. The collaboration includes a fixed configuration fee followed by platform and services subscription fees, enabling patient medical record aggregation and providing pharmaceutical companies access to de-identified data for monitoring outcomes and prescription trends.
DarioHealth Corp. (DRIO) has secured a new contract with a regional health plan in the Medicaid space, marking its eighth health plan partnership and third Medicaid client. The agreement includes implementation of Dario's full suite of cardiometabolic solutions for nearly 10,000 Medicaid members. The health plan selected Dario based on its proven success with another regional plan and its ability to engage diverse populations through personalized experiences across multiple channels. The contract is expected to generate revenue starting in Q4 2024.
DarioHealth Corp. (Nasdaq: DRIO) announced it will release its Q3 2024 financial results on Thursday, November 7th, 2024, before market opens. The company will host a conference call and webcast at 8:30 AM ET, led by CEO Erez Raphael and CCO Steven Nelson. The earnings call will be accessible via phone dial-in and webcast, with replay available until November 21, 2024.
DarioHealth Corp. (Nasdaq: DRIO) has announced the complete integration of Twill's behavioral health and navigation capabilities into its digital health platform. This integration creates a comprehensive solution for multi-chronic condition management under the Dario brand. The expanded platform now addresses both mental and physical aspects of health across all existing chronic condition management programs.
Key features of the integrated platform include:
- Vertical expansion: Incorporating behavioral health support into chronic condition management
- Horizontal expansion: Integrating Twill's navigation capabilities to guide users through their health journey
- Unified brand: All solutions now under the Dario name
- Four core offerings: Dario Connect (Wellbeing & Navigation), Dario Mind (Behavioral Health), Dario Health (Cardiometabolic Care), and Dario Move (Musculoskeletal Health)
The integration aims to provide a more personalized and effective approach to care by unifying data across mental and physical health, potentially solving issues of point solution fatigue and poor engagement for payers, employers, and pharma companies.
DarioHealth Corp. (Nasdaq: DRIO) has announced a new AARP member benefit set to launch in January 2025, offering digital behavioral health and well-being solutions through Twill by Dario. This initiative aims to address growing mental health needs among people 50-plus, including issues like loneliness, stress, and anxiety. The benefit will provide AARP members with free access to Dario's premium Twill by Dario subscription service, along with a custom collection of 5 activity tracks.
Dario's user-centric platform has demonstrated success in driving engagement and positively impacting health by reducing symptoms of depression and loneliness, and improving overall perceptions of wellbeing. The company's technologies will offer personalized user navigation and simplify the process of recommending and implementing appropriate care and support modalities.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
